



BÖLÜM 22

COVID-19 Enfeksiyonu Semptomları ve Tanısı

Aysu AYRANCI¹
Melike YÜKSEL YAVUZ²

Covid-19 Enfeksiyonu Semptomları

Koronavirüs ilişkili hastalık-2019 (COVID-19) vakaları, asemptomatik veya semptomatik olabilir. Asemptomatik vakalar semptom ve sistem tutulumlarına ait bulguları olmayıp, SARS-CoV-2 enfeksiyonu kanıtlanmış vakalardır. Asemptomatik vakalarda ilerleyen günlerde semptom gelişebilse de semptomsuz da devam edebilmektedir. Bir derlemede, SARS-CoV-2 ile enfekte olan kişilerin yüzde 33'ünün hiçbir zaman semptom gelişmediği vurgulanmıştır (1). Bu oranlar, ülkelere ve viral mutasyonlara göre değişmektedir. COVID-19'lu vakaları semptomlarına ve sistem tutulumlarına göre hafif, orta, ciddi ve kritik hastalığa sahip olanlar olarak sınıflayabiliriz (2).

Çin Hastalık Kontrol ve Önleme Merkezi, oranlarına bakacak olursak; Hafif hastalık oranı %81, ciddi hastalık oranı %14, kritik hastalık oranı %5 ve mortalite %2,3' dir (3).

The National Institutes of Health (NIH) sınıflamasına göre;

- *Asemptomatik veya Presemptomatik Enfeksiyon:* Virolojik bir test kullanarak SARS-CoV-2 için pozitif testi olan ancak COVID-19 ile tutarlı semptomları olmayan kişilerdir.

¹ Dr. Öğr. Üyesi, İzmir Bakırçay Üniversitesi, Çiğli Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları, draysu87@gmail.com

² Uzm. Dr., İzmir Bakırçay Üniversitesi, Çiğli Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları, yukselmelike@windowslive.com

KAYNAKLAR

1. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review. *Ann Intern Med* 2021.
2. National Health Commission of People's Republic of China. Diagnostic and treatment plan of Coronavirus disease 2019. 7th ed. (03.2021 tarihinde <http://www.nhc.gov.cn/yzygj/s7653p/202003/.shtml>)' den ulaşılmıştır.
3. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 2020; 323:1239.
4. Clinical Spectrum of SARS-CoV-2 Infection. Retrieved from (Last Updated: December 17, 2020) (03.2021 tarihinde <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/.html>)' den ulaşılmıştır.
5. Manaf Al-Q, Salman A, AbdulKarim A, et al. The prevalence of asymptomatic and symptomatic COVID-19 in a cohort of quarantined subjects. *Int J Infect Dis.* 2021 Jan; 102: 285–288.
6. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med.* 2020 May 5;172(9):577–82.
7. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395:1054–1062.
8. Centers for Disease Control and Prevention. People who are at higher risk for severe illness. (Accessed on April 01, 2020). (03.2021 tarihinde <https://www.cdc.gov/coronavirus/2019-n-cov/need-extra-precautions/people-at-higher-risk.html>) ulaşılmıştır.
9. Lauer SA, Grantz KH, Bi Q, Jones FK., et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med* 2020; 172:577–82.
10. Sama IE, Ravera A, Santema BT, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. *Eur Heart J.* 2020; 41:1810–1817.
11. He X, Cheng X, Feng X, et al. Clinical Symptom Differences Between Mild and Severe COVID-19 Patients in China: A Meta-Analysis. *Front Public Health.* 2021; 8:561264.
12. Matsuyama S, Nao N, Shirato K, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. *Proc Natl Acad Sci USA* 117: 7001–7003, 2020.
13. Saghazadeh A, Rezaei N. Immune-epidemiological parameters of the novel coronavirus -a perspective. *Expert Rev Clin Immunol* 16: 465–470, 2020.
14. COVID-19 (SARS-CoV-2 Enfeksiyonu) Genel Bilgiler, Epidemiyoloji ve Tanı Rehberi, (syf:17) T.C. Sağlık Bakanlığı 7 Aralık 2020, Ankara.
15. Coronavirus disease (COVID-19) 12 October 2020. (03.2021 tarihinde <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/.html>) ulaşılmıştır.
16. Andrea L, Cosimo de F. Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms. *Ear, Nose & Throat Journal* 1–8. 2020.
17. Ollarves-Carrero MF, Rodriguez-Morales AG, Bonilla-Aldana DK, et al. Anosmia in a healthcare worker with COVID-19 in Madrid, Spain. *Travel Med Infect Dis* 35:101666
18. Al-Ani RM, Acharya D. Prevalence of Anosmia and Ageusia in Patients with COVID-19 at a Primary Health Center, Doha, Qatar [published online ahead of print, 2020 Aug 19]. *Indian J Otolaryngol Head Neck Surg.* 2020;1-7. doi:10.1007/s12070-020-02064-9.

19. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med* 2020. <https://doi.org/10.1056/NEJMoa2002032>.
20. Luca C, Aurelio S, Ahmed N, et al. Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. *medRxiv* 2020.04.19.20054262.
21. Walid H, Malik B, Agnieszka B, et al. Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19. *Journal of Molecular and Cellular Cardiology* 153 (2021) 72–85.
22. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus Disease 2019 Case Surveillance- United States, January 22-May 30, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69:759.
23. Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. *J Inf Secur.* 2020;80(6):656–65.
24. Cole-Jeffrey C.T., Liu M., Katovich M.J, et al. ACE2 and microbiota: emerging targets for cardiopulmonary disease therapy. *J Cardiovasc Pharmacol.* 2015; 66:540–550.
25. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2020; 5:667–78. [10.1016 / S2468-1253 \(20\) 30126-6](https://doi.org/10.1016/S2468-1253(20)30126-6).
26. Rokkas T. Gastrointestinal involvement in COVID-19: a systematic review and meta-analysis. *Ann Gastroenterol.* 2020;33(4):355-365.
27. Khoshdel-Rad N., Zahmatkesh E., Shpichka A, et al. Outbreak of chronic renal failure: will this be a delayed heritage of COVID-19? *J Nephrol.* 2020:1–3.
28. Bansal M. Kardiyovasküler hastalık ve COVID-19. *Diabetes Metab Syndr.* 2020; 14: 247–250.
29. Soumya R. S, Govindan Unni T, Raghu K. G. Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports. *Cardiovasc Drugs Ther.* 2020 Sep 14: 1–15.
30. Bader F, Manla Y, Atallah B, et al. Heart failure and COVID-19. *Heart Fail Rev.* 2021 Jan;26(1):1-10.
31. Banu Özen B, İlknur Güçlü A. COVID-19 ile ilişkili Nörolojik Komplikasyonlar South. *Clin. Ist. Euras.* 2020;31(Suppl):26-30.
32. Berlit, P, Bösel, J, Gahn, G, et al. Neurological manifestations of COVID-19- guideline of the German society of neurology. *Neurol. Res. Pract.* 2, 51 (2020).
33. Hai-Yang W, Xue-Lin L, Zhong-Rui Y, et al. Potential neurological symptoms of COVID-19. *Ther Adv Neurol Disord* 2020, Vol. 13: 1–2.
34. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus Disease 2019 Case Surveillance- United States, January 22-May 30, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69:759.
35. Mark A E, Laura B, Bhagteshwar S, et al. Neurological associations of COVID-19. *Lancet Neurol* 2020; 19: 767–83.
36. Tamar W, Nicole H. The neurological symptoms of COVID-19: a systematic overview of systematic reviews, comparison with other neurological conditions and implications for healthcare services. *Article in Therapeutic Advances in Chronic Disease · January 2021.*
37. Mao L, Wang M, Chen S, et al. Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. *JAMA Neurol.* (2020) 77:683–90.
38. Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. *Military Medical Research.* 2020;7(1):11.
39. Fadaka AO, Sibuyi NRS, Adewale OB, et al. Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2. *The Journal of international medical research.* 2020;48(8):300060520949077.

40. Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. *Proceedings of the National Academy of Sciences of the United States of America*. 2020;117(21):11727-34.
41. Gordon DE, Jang GM, Bouhaddou M, et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature*. 2020;583(7816):459-68.
42. WHO (2021). WHO Coronavirus (COVID-19) Dashboard. (15.05.2021 tarihinde <https://covid19.who.int/> adresinden ulaşılmıştır).
43. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *The New England journal of medicine*. 2020;382(8):727-33.
44. Mao K, Zhang H, Yang Z. Can a Paper-Based Device Trace COVID-19 Sources with Wastewater-Based Epidemiology? *Environmental science & technology*. 2020;54(7):3733-5.
45. Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. *The Cochrane database of systematic reviews*. 2020;7(7):Cd013665.
46. Cohen PA, Hall LE, John JN, Rapoport AB. The Early Natural History of SARS-CoV-2 Infection: Clinical Observations From an Urban, Ambulatory COVID-19 Clinic. *Mayo Clinic proceedings*. 2020;95(6):1124-6.
47. Tostmann A, Bradley J, Bousema T, et al. Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020. *Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin*. 2020;25(16).
48. Makaronidis J, Mok J, Balogun N, et al. Seroprevalence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and/or taste in a community-based population in London, UK: An observational cohort study. *PLoS medicine*. 2020;17(10):e1003358.
49. Sağlık Bakanlığı (2020). Covid-19 Rehberi Genel Bilgiler, Epidemiyoloji ve Tanı. (07.12.2020 tarihinde <https://covid19.saglik.gov.tr/Eklenti/39551/0covid-19rehberigenel-bilgiler-epidemiyolojivetanipdf.pdf> adresinden ulaşılmıştır).
50. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *The New England journal of medicine*. 2021;384(6):533-40.
51. Shereen MA, Khan S, Kazmi A, et al. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *Journal of advanced research*. 2020;24:91-8.
52. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Annals of internal medicine*. 2020;172(9):577-82.
53. Adhikari SP, Meng S, Wu YJ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. *Infectious diseases of poverty*. 2020;9(1):29.
54. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020;75(7):1730-41.
55. Akinbami LJ, Petersen LR, Sami S, et al. COVID-19 symptoms and SARS-CoV-2 antibody positivity in a large survey of first responders and healthcare personnel, May-July 2020. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. 2021.
56. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature medicine*. 2020;26(5):672-5.
57. Ganyani T, Kremer C, Chen D, et al. Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data, March 2020. *Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin*. 2020;25(17).

58. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020;581(7809):465-9.
59. WHO (2020). Diagnostic testing for SARS-CoV-2. (05.11.2020 tarihinde <https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2> adresinden ulaşılmıştır).
60. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *Jama*. 2020;323(18):1843-4.
61. Cevik M, Bamford CGG, Ho A. COVID-19 pandemic-a focused review for clinicians. *Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2020;26(7):842-7.
62. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)*. 2020;395(10223):497-506.
63. Pan Y, Zhang D, Yang P, et al. Viral load of SARS-CoV-2 in clinical samples. *The Lancet Infectious diseases*. 2020;20(4):411-2.
64. Sutjipto S, Lee PH, Tay JY, et al. The Effect of Sample Site, Illness Duration, and the Presence of Pneumonia on the Detection of SARS-CoV-2 by Real-time Reverse Transcription PCR. *Open forum infectious diseases*. 2020;7(9):ofaa335.
65. COVID-19 Investigation Team. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. *Nature medicine*. 2020;26(6):861-8.
66. Lai CKC, Chen Z, Lui G, et al. Prospective Study Comparing Deep Throat Saliva With Other Respiratory Tract Specimens in the Diagnosis of Novel Coronavirus Disease 2019. *The Journal of infectious diseases*. 2020;222(10):1612-9.
67. Hammitt LL, Kazungu S, Welch S, et al. Added value of an oropharyngeal swab in detection of viruses in children hospitalized with lower respiratory tract infection. *Journal of clinical microbiology*. 2011;49(6):2318-20.
68. Ek P, Böttiger B, Dahlman D, et al. A combination of naso- and oropharyngeal swabs improves the diagnostic yield of respiratory viruses in adult emergency department patients. *Infectious diseases (London, England)*. 2019;51(4):241-8.
69. Goff J, Rowe A, Brownstein JS, et al. Surveillance of Acute Respiratory Infections Using Community-Submitted Symptoms and Specimens for Molecular Diagnostic Testing. *PLoS currents*. 2015;7.
70. Wang WK, Chen SY, Liu IJ, et al. Detection of SARS-associated coronavirus in throat wash and saliva in early diagnosis. *Emerging infectious diseases*. 2004;10(7):1213-9.
71. To KK, Lu L, Yip CC, et al. Additional molecular testing of saliva specimens improves the detection of respiratory viruses. *Emerging microbes & infections*. 2017;6(6):e49.
72. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. *The New England journal of medicine*. 2020;383(13):1283-6.
73. Weissleder R, Lee H, Ko J, et al. COVID-19 diagnostics in context. *Science translational medicine*. 2020;12(546).
74. FDA (2020). False Positive Results with BD SARS-CoV-2 Reagents for the BD Max System - Letter to Clinical Laboratory Staff and Health Care Providers. (10.07.2020 tarihinde <https://www.fda.gov/medical-devices/letters-health-care-providers/false-positive-results-bd-sars-cov-2-reagents-bd-max-system-letter-clinical-laboratory-staff-and> adresinden ulaşılmıştır).
75. Chen W, Lan Y, Yuan X, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. *Emerging microbes & infections*. 2020;9(1):469-73.

76. Ling Y, Xu SB, Lin YX, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. *Chinese medical journal*. 2020;133(9):1039-43.
77. Yan Y, Chang L, Wang L. Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures. *Reviews in medical virology*. 2020;30(3):e2106.
78. Zhang W, Du RH, Li B,, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. *Emerging microbes & infections*. 2020;9(1):386-9.
79. Wu Y, Guo C, Tang L, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. *The lancet Gastroenterology & hepatology*. 2020;5(5):434-5.
80. Chen C, Gao G, Xu Y, et al. SARS-CoV-2-Positive Sputum and Feces After Conversion of Pharyngeal Samples in Patients With COVID-19. *Annals of internal medicine*. 2020;172(12):832-4.
81. Gupta S, Parker J, Smits S, et al. Persistent viral shedding of SARS-CoV-2 in faeces - a rapid review. *Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland*. 2020;22(6):611-20.
82. Yongchen Z, Shen H, Wang X, et al. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. *Emerging microbes & infections*. 2020;9(1):833-6.
83. Atkinson B, Petersen E. SARS-CoV-2 shedding and infectivity. *Lancet (London, England)*. 2020;395(10233):1339-40.
84. Lescure FX, Bouadma L, Nguyen D,, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. *The Lancet Infectious diseases*. 2020;20(6):697-706.
85. Lui G, Ling L, Lai CK, et al. Viral dynamics of SARS-CoV-2 across a spectrum of disease severity in COVID-19. *The Journal of infection*. 2020;81(2):318-56.
86. Chang L, Zhao L, Gong H, et al. Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations. *Emerging infectious diseases*. 2020;26(7):1631-3.
87. Kwon SY, Kim EJ, Jung YS, et al. Post-donation COVID-19 identification in blood donors. *Vox sanguinis*. 2020;115(8):601-2.
88. Caruana G, Croxatto A, Coste AT, et al. Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results. *Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2020;26(9):1178-82.
89. The Centre for Evidence-Based Medicine (2020). What tests could potentially be used for the screening, diagnosis and monitoring of COVID-19 and what are their advantages and disadvantages. (20.04.2020 tarihinde <https://www.cebm.net/covid-19/what-tests-could-potentially-be-used-for-the-screening-diagnosis-and-monitoring-of-covid-19-and-what-are-their-advantages-and-disadvantages/> adresinden ulaşılmıştır).
90. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. *Jama*. 2020;323(22):2249-51.
91. Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. *Annals of internal medicine*. 2020;173(4):262-7.
92. Hong KH, Lee SW, Kim TS, et al. Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea. *Annals of laboratory medicine*. 2020;40(5):351-60.
93. Tang YW, Schmitz JE, Persing DH, et al. Laboratory Diagnosis of COVID-19: Current Issues and Challenges. *Journal of clinical microbiology*. 2020;58(6).

94. Lippi G, Simundic AM, et al. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). *Clinical chemistry and laboratory medicine*. 2020;58(7):1070-6.
95. Patel R, Babady E, Theel ES, et al. Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: Value of Diagnostic Testing for SARS-CoV-2/COVID-19. *mBio*. 2020;11(2).
96. Chan CM, Tse H, Wong SS, et al. Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus. *Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology*. 2009;45(1):54-60.
97. Chan-Yeung M, Xu RH. SARS: epidemiology. *Respirology (Carlton, Vic)*. 2003;8 Suppl(-Suppl 1):S9-14.
98. Liu Y, Eggo RM, Kucharski AJ. Secondary attack rate and superspreading events for SARS-CoV-2. *Lancet (London, England)*. 2020;395(10227):e47.
99. Roda A, Cavaleri S, Di Nardo F, et al. Dual lateral flow optical/chemiluminescence immunosensors for the rapid detection of salivary and serum IgA in patients with COVID-19 disease. *Biosensors & bioelectronics*. 2021;172:112765.
100. CDC (2021). Interim Guidelines for Collecting and Handling of Clinical Specimens for COVID-19 Testing. (26.02.2021 tarihinde <https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html> adresinden ulaşılmıştır).
101. Stowell SR, Guarner J. Role of Serology in the Coronavirus Disease 2019 Pandemic. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. 2020;71(8):1935-6.
102. Bryant JE, Azman AS, Ferrari MJ, et al. Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward. *Science immunology*. 2020;5(47).
103. Mulchandani R, Jones HE, Taylor-Phillips S, et al. Accuracy of UK Rapid Test Consortium (UK-RTC) "AbC-19 Rapid Test" for detection of previous SARS-CoV-2 infection in key workers: test accuracy study. *BMJ (Clinical research ed)*. 2020;371:m4262.